-¹Ì FTA°¡ ó¹æÀǾàǰÀÇ °¡°Ý°ú µîÀç¿¡ ¹ÌÄ¡´Â ¿µÇâ ¿¹Ãø: È£-¹Ì FTAÀÇ °æÇèÀ» Áß½ÉÀ¸·Î
Prediction of the Effect of the Korea-United States FTA on the Reimbursement and Price of Prescription Drugs: Based on Australia-US FTA

º¸°Ç°æÁ¦¿Í Á¤Ã¥¿¬±¸ 2014³â 20±Ç 2È£ p.21 ~ p.48

¼Õ°æº¹(Son Kyung-Bok) - ¼­¿ï´ëÇб³ º¸°Ç´ëÇпø
ÀÌÅÂÁø(Lee Tae-Jin) - ¼­¿ï´ëÇб³ º¸°Ç´ëÇпø

Abstract

À̹ø ¿¬±¸´Â ÇÑ-¹Ì FTAÀÇ ¿µÇâÀ» ¿¹ÃøÇϱâ À§ÇÑ ¹æ¹ýÀ¸·Î È£-¹Ì FTAÀÇ »ç·Ê¸¦ ºÐ¼®Çϰí, Á¤Ã¥Àû ÇÔÀǸ¦ µµÃâÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. À̸¦ À§ÇÏ¿© ÇÑ-¹Ì FTA ÇùÁ¤¹®°ú È£-¹Ì FTA ÇùÁ¤¹®À» ºñ±³ ºÐ¼®Çϰí, È£-¹Ì FTAÀÇ È¿°ú¸¦ ÀǾàǰÀÇ °¡°Ý°ú µîÀç½ÃÁ¡ º¯È­¸¦ Áß½ÉÀ¸·Î Á¦½ÃÇÏ¿´´Ù. ÇùÁ¤¹®ÀÇ °æ¿ì ÀüüÀûÀ¸·Î È£ÁÖ¿Í Çѱ¹¿¡¼­ À¯»çÇÑ ¾ÈÀÌ Á¦½ÃµÇ¾ú´Ù. ÀÌ´Â ÀǾàǰ ºÎºÐ Çù»ó¿¡ À־ ¹Ì±¹ÀÌ »ó´ëÀû ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ¾ú°í, Çù»ó °úÁ¤¿¡¼­ ¹Ì±¹ Á¦¾à¾÷°èÀÇ ÀǰßÀ» ¹Ì±¹ ¹«¿ª ´ëÇ¥ºÎ(USTR)°¡ Ãæ½ÇÇÏ°Ô ¹Ý¿µÇÑ °ÍÀ¸·Î º¼ ¼ö ÀÖ´Ù. È£ÁÖÀÇ »ç·Ê¿¡¼­ ó¹æÀǾàǰÀÇ °¡°Ý¿¡ °¡Àå Å« ¿µÇâÀ» ÁØ ¿äÀÎÀº ±¹°¡º¸°Ç¹ý °³Á¤À» ÅëÇÑ ÂüÁ¶°¡°ÝÁ¦ÀÇ º¯È­¿´´Ù. È£-¹Ì FTA ÇùÁ¤¹®ÀÇ °æ¿ì ÂüÁ¶°¡°ÝÁ¦¸¦ Á÷Á¢ÀûÀ¸·Î ¾ð±ÞÇϰí ÀÖÁö´Â ¾Ê¾ÒÁö¸¸ Çõ½Å¼º Á¶Ç× ¹× ÀǾàǰ ÀÛ¾÷¹Ý Ȱµ¿À» ÅëÇÏ¿© ÂüÁ¶°¡°ÝÁ¦°¡ º¯È­µÇ´Â ¸ð½ÀÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù. ¶ÇÇÑ Ã³¹æÀǾàǰ µîÀç¿¡ ¿µÇâÀ» ÁØ ¿äÀÎÀ¸·Î´Â ÀǾàǰ ÀÛ¾÷¹ÝÀÇ È°µ¿, Çã°¡-ƯÇã ¿¬°èÁ¦µµ, ÀÚ·áµ¶Á¡ÀÌ ÀÖ¾ú´Ù. È£ÁÖÀÇ »ç·Ê´Â Çѱ¹¿¡ ¸î °¡Áö ½Ã»çÁ¡À» Á¦½ÃÇÑ´Ù. ¸ÕÀú Çõ½Å¼ºÀÇ ÇØ¼®¿¡ ´ëÇÑ ºÒÈ®½Ç¼ºÀ» ÇØ¼ÒÇϱâ À§ÇÏ¿© Çõ½Å¼ºÀÇ Àǹ̸¦ ¾à»ç¹ý µîÀ» ÅëÇÏ¿© Á¦½ÃÇÏ´Â °ÍÀº ÇâÈÄ ÇùÁ¤¹® ÀÌÇàÀÇ ºÒÈ®½Ç¼º ÇØ¼Ò¿¡ µµ¿òÀ» ÁÙ °ÍÀÌ´Ù. ¶ÇÇÑ ÀǾàǰ µîÀç¿¡ À־ ÀǾàǰÀÇ ÁöÀûÀç»ê±Ç °­È­·Î ÀÎÇÑ ¹«ºÐº°ÇÑ ¼Ò¼Û Áõ°¡ ¹× º¹Á¦ ÀǾàǰ »ê¾÷ À§ÃàÀº ¿ì·ÁÇÒ ¸¸ÇÏ´Ù. Çã°¡-ƯÇã ¿¬°èÁ¦µµÀÇ °æ¿ì ÀÚ·áµ¶Á¡°ú´Â ´Ù¸£°Ô ±âÁ¸¿¡ Á¸ÀçÇÏÁö ¾Ê¾Ò´ø »õ·Î¿î Á¦µµ°¡ µµÀÔµÈ °ÍÀ¸·Î ÀÌ¿Í °ü·ÃÇÑ ¹ý°ú Á¦µµ¸¦ Á¤ºñÇÏ´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù.
This study analyzed Australia-United States Free Trade Agreement (AUSFTA) and Korea-United States Free Trade Agreement (KORUSFTA) focusing on medicines and medicines related intellectual property provisions. Also this study analyzed AUSFTA¡¯s empirical case which came into force in 2005. Alteration of reference pricing by the amendments of the National Health Act in 2007 was the most effective factor that influenced the price of prescription drugs in Australia. Although AUSFTA didn``t include reference pricing directly, provisions of agreement changed reference pricing indirectly through the amendment of the National Health Act. In the price of prescription drug, innovation provisions can be used as rhetoric so it can change current policy or system indirectly. To resolve uncertainty in interpretation of innovation, we need to identify innovation in detail in our current law system. Also it is reasonable to worry about increased legal action against patent infringement and its negative effect on the generic pharmaceutical industry. So how to make patent linkage related law and policy may be the most important factor that can influence the effect of the patent linkage in Korea.

Ű¿öµå

Çѱ¹-¹Ì±¹ ÀÚÀ¯¹«¿ªÇùÁ¤, Çõ½Å¼º, Çã°¡-ƯÇã ¿¬°èÁ¦µµ, ÀÚ·áµ¶Á¡
FTA, KORUSFTA, AUSFTA, Innovation, Patent linkage, Data exclusivity
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå